Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Tolvaptan
Drug ID BADD_D02246
Description Tolvaptan is used to treat low blood sodium levels (hyponatremia) associated with various conditions like congestive heart failure, cirrhosis, and syndrome of inappropriate antidiuretic hormones (SIADH). FDA approved on May 19, 2009.
Indications and Usage Treatment of symptomatic and resistant to fluid restriction euvolemic or hypervolemic hyponatremia associated with congestive heart failure, SIADH, and cirrhosis.
Marketing Status approved
ATC Code C03XA01
DrugBank ID DB06212
KEGG ID D01213
MeSH ID D000077602
PubChem ID 216237
TTD Drug ID D03KZM
NDC Product Code 31722-869; 59148-088; 60505-4704; 65977-0100; 59148-082; 67877-637; 59148-079; 60505-4318; 60505-4705; 46602-0031; 59148-089; 14501-0066; 31722-868; 59148-083; 46602-0028; 46602-0030; 49884-770; 59148-020; 67877-635; 14501-0085; 57884-0027; 49884-768; 59148-021; 59148-080; 60505-4317; 67877-636; 46602-0027; 46602-0029; 60862-008; 59148-087
UNII 21G72T1950
Synonyms Tolvaptan | 7-Chloro-5-hydroxy-1-(2-methyl-4-(2-methylbenzoylamino)benzoyl)2,3,4,5-tetrahydro-1H-1-benzazepine | Samsca | OPC 41061 | OPC-41061 | OPC41061
Chemical Information
Molecular Formula C26H25ClN2O3
CAS Registry Number 150683-30-0
SMILES CC1=CC=CC=C1C(=O)NC2=CC(=C(C=C2)C(=O)N3CCCC(C4=C3C=CC(=C4)Cl)O)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Polyuria20.02.03.0020.001559%Not Available
Prothrombin level increased13.01.02.011--Not Available
Prothrombin time prolonged13.01.02.012--Not Available
Prurigo23.03.04.017--Not Available
Pruritus23.03.12.001--
Pulmonary congestion22.01.03.002; 02.05.02.002; 24.03.08.0010.000087%Not Available
Pulmonary embolism24.01.06.001; 22.06.02.001--Not Available
Pulmonary fibrosis22.01.02.0060.000058%
Pulmonary oedema22.01.03.003; 02.05.02.0030.000145%
Pulmonary thrombosis24.01.06.002; 22.06.02.0030.000058%Not Available
Pyrexia08.05.02.003--
Rash23.03.13.001--Not Available
Rash pruritic23.03.13.030--Not Available
Renal cyst20.01.04.001; 16.27.01.0010.000058%Not Available
Renal disorder20.01.02.0020.000419%Not Available
Renal failure20.01.03.0050.000535%Not Available
Renal pain20.02.03.0030.000204%Not Available
Respiratory failure22.02.06.002; 14.01.04.0030.000233%
Retinal detachment12.01.04.004; 06.09.03.003--
Rhabdomyolysis15.05.05.002--
Rheumatoid arthritis15.01.03.001; 10.04.06.001--Not Available
Rotator cuff syndrome12.01.07.018; 15.01.08.002--
Shock24.06.02.0020.000145%Not Available
Skin disorder23.03.03.007--Not Available
Skin ulcer24.04.03.007; 23.07.03.0030.000058%
Sleep disorder19.02.04.0010.000343%Not Available
Stevens-Johnson syndrome11.07.01.005; 10.01.01.045; 23.03.01.007; 12.03.01.0140.000058%
Subarachnoid haemorrhage24.07.04.004; 17.08.01.010; 12.01.10.0110.000174%Not Available
Sudden death08.04.01.003; 02.03.04.0130.000145%
Swelling08.01.03.015--Not Available
The 7th Page    First    Pre   7 8 9 10    Next   Last    Total 10 Pages